Bio-Rad Laboratories, Inc. $BIO Shares Sold by Acadian Asset Management LLC

Acadian Asset Management LLC lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 30.0% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 51,410 shares of the medical research company’s stock after selling 22,021 shares during the period. Acadian Asset Management LLC owned about 0.19% of Bio-Rad Laboratories worth $12,400,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd lifted its holdings in Bio-Rad Laboratories by 3,633.3% in the second quarter. Caitong International Asset Management Co. Ltd now owns 112 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 109 shares during the period. Quarry LP purchased a new stake in Bio-Rad Laboratories during the first quarter worth $29,000. Allworth Financial LP grew its position in Bio-Rad Laboratories by 260.0% during the first quarter. Allworth Financial LP now owns 144 shares of the medical research company’s stock valued at $36,000 after buying an additional 104 shares during the period. UMB Bank n.a. increased its holdings in Bio-Rad Laboratories by 89.8% in the second quarter. UMB Bank n.a. now owns 167 shares of the medical research company’s stock valued at $40,000 after buying an additional 79 shares in the last quarter. Finally, Headlands Technologies LLC raised its position in shares of Bio-Rad Laboratories by 64.1% in the first quarter. Headlands Technologies LLC now owns 356 shares of the medical research company’s stock worth $87,000 after acquiring an additional 139 shares during the period. 65.24% of the stock is owned by institutional investors and hedge funds.

Bio-Rad Laboratories Trading Up 2.1%

Shares of Bio-Rad Laboratories stock opened at $313.82 on Wednesday. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17. The company has a fifty day simple moving average of $300.66 and a 200-day simple moving average of $268.65. The stock has a market cap of $8.49 billion, a price-to-earnings ratio of -12.91 and a beta of 1.04. Bio-Rad Laboratories, Inc. has a 12-month low of $211.43 and a 12-month high of $373.69.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Wednesday, October 29th. The medical research company reported $2.26 earnings per share for the quarter, missing analysts’ consensus estimates of $2.30 by ($0.04). The company had revenue of $653.00 million during the quarter, compared to analysts’ expectations of $651.30 million. Bio-Rad Laboratories had a negative net margin of 26.43% and a positive return on equity of 4.18%. Bio-Rad Laboratories’s revenue was up .5% on a year-over-year basis. During the same period last year, the firm earned $2.01 earnings per share. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Insider Buying and Selling at Bio-Rad Laboratories

In other news, EVP James Barry sold 700 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $306.18, for a total transaction of $214,326.00. Following the transaction, the executive vice president directly owned 510 shares in the company, valued at approximately $156,151.80. This trade represents a 57.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 17.06% of the company’s stock.

Analyst Upgrades and Downgrades

BIO has been the subject of several recent analyst reports. Royal Bank Of Canada lifted their price target on Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a research note on Friday, August 1st. Weiss Ratings raised Bio-Rad Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, October 30th. Zacks Research raised shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Wells Fargo & Company increased their target price on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Finally, Wall Street Zen upgraded Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, November 1st. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $358.50.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.